GoldenGolden
Affinivax

Affinivax

Affinivax is a vaccine Discovery Technology founded in 2014 by Richard Malley, MD, Fan Zhang, PhD, Yingjie Lu, PhD and Kamran Tavangar.

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

April 23, 2020
Affinivax raises a $120,000,000 series B round.
April 23, 2020
Affinivax raises a $120,000,000 series B round from Bain Capital Life Sciences, Viking Global Investors and Ziff Capital Partners.
February 5, 2016
Affinivax raises a $2,500,000 series A round from Bill & Melinda Gates Foundation.
February 5, 2016
Affinivax raises a $2,500,000 series A round from Bill & Melinda Gates Foundation.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 5, 2021
BioSpace
Affinivax, Inc. ("Affinivax"), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPSTM (Multiple Antigen Presenting System) platform , today announced that Elizabeth Radcliffe has joined the company as Chief Financial Officer.
BioSpace
April 20, 2021
BioSpace
Affinivax, Inc. ("Affinivax"), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPSTM (Multiple Antigen Presenting System) platform, today announced that Stuart Chaffee, PhD, has joined the company as Chief Business Officer.
Ben Adams
January 8, 2021
FierceBiotech
After getting off a meaty $120 million round in April, the height of the first wave of COVID-19 infections in the West, Affinivax is a clear indicator that infectious disease and vaccine work is here to stay.
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.